TRLV — Trulieve Cannabis Corp. Subordi
Is TRLV overbought or oversold? Here is the current MarketMoodz read.
Trulieve Cannabis Corp. Subordi (TRLV) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $10.07. The rating moved from Neutral to Strong Oversold on November 16, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$10.07
- Last changeMoved from Neutral to Strong Oversold on November 16, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Trulieve is a large multi-state cannabis operator with consistent retail exposure and potential upside from state legalization and product/margin improvement. Near-term performance will hinge on cost control, store-level profitability and access to capital; federal banking and tax constraints remain key structural headwinds. Absent clear positive earnings surprises or major regulatory relief, the name is likely to trade with consolidation and volatility, with upside tied to execution on margins, prudent balance-sheet management and gradual expansion in favorable states.
Key factors
- Market position as a multi-state operator with a large retail footprint and brand recognition in core markets
- Revenue growth potential from continued state-level legalization and retail expansion, plus product mix diversification (flower, extracts, vapes, edibles)
- Margin pressure risk from wholesale pricing, cost of goods sold and regulatory/tax burdens that could constrain near-term profitability
- Balance sheet and liquidity profile that influence ability to invest, complete M&A or withstand regulatory/compliance costs (debt servicing and capital access are material)
- Limited visible social sentiment and sparse near-term catalysts in public feeds; attention likely to remain on earnings and state regulatory developments
- Industry-wide banking, federal legality and tax (e.g., 280E) constraints that continue to affect operating flexibility and after-tax cash flow
Risks
- Federal illegality and restrictive banking access that raise operating costs and complicate capital and treasury operations
- State-level regulatory changes, license revocations or tighter compliance enforcement that can disrupt stores or create remediation costs
- Price competition and oversupply in core markets leading to margin compression and slower top-line growth
- High leverage or refinancing needs that could limit strategic options or force equity raises at dilutive levels
- Adverse tax treatment (e.g., 280E) and local excise taxes that pressure net income and free cash flow
- Execution risk on integrations, store openings and inventory management that could exacerbate cash burn if growth assumptions slip
See today's live rating, score and targets
Members see the live hourly rating for TRLV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.